TitleBCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
Publication TypeJournal Article
Year of Publication2007
AuthorsParekh, Samir, Polo Jose M., Shaknovich Rita, Juszczynski Przemyslaw, Lev Paola, Ranuncolo Stella M., Yin Yingnan, Klein Ulf, Cattoretti Giorgio, Favera Riccardo Dalla, Shipp Margaret A., and Melnick Ari
Date Published2007 Sep 15
KeywordsBlotting, Western, Cell Differentiation, Cell Survival, Chromatin Immunoprecipitation, DNA-Binding Proteins, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Immunoenzyme Techniques, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm Proteins, Nuclear Proteins, Nuclear Receptor Co-Repressor 1, Nuclear Receptor Co-Repressor 2, Oligonucleotide Array Sequence Analysis, Positive Regulatory Domain I-Binding Factor 1, Proto-Oncogene Proteins c-bcl-6, Repressor Proteins, Reverse Transcriptase Polymerase Chain Reaction, RNA, Messenger, RNA, Neoplasm, RNA, Small Interfering, Signal Transduction, Tissue Array Analysis, Transcription Factors, Transcription, Genetic

<p>The BCL6 transcriptional repressor is the most commonly involved oncogene in diffuse large B-cell lymphomas (DLBCLs). Constitutive expression of BCL6 mediates lymphomagenesis through aberrant proliferation, survival, and differentiation blockade. Binding of BCL6 to the SMRT/N-CoR corepressors mediates the BCL6 survival effect in DLBCL. Although the basis for differentiation blockade is unknown in DLBCL, recent data suggest that BCL6 binding to the MTA3 corepressor might be involved. We report that BCL6 and MTA3 are coexpressed in normal germinal center B cells and DLBCL. Depletion of MTA3 in DLBCL cells induced a differentiation-related BCL6 target gene (PRDM1), but not target genes involved in survival. Accordingly, MTA3 and PRDM1 expression are mutually exclusive in germinal center B cells. We performed chromatin immunoprecipitation (ChIP)-on-chip mapping of the PRDM1 locus, identifying a novel BCL6 binding site on intron 3 of the PRDM1 gene, and show that BCL6 recruits MTA3 to this site. In DLBCL cells, MTA3 depletion induced plasmacytic differentiation but did not decrease viability of DLBCL cells. However, MTA3 depletion synergized with a specific BCL6 inhibitor that blocks SMRT/N-CoR binding to decrease DLBCL viability. Taken together, these results show that BCL6 regulates distinct transcriptional programs through the SMRT/N-CoR and MTA3 corepressors, respectively, and provides a basis for combinatorial therapeutic targeting of BCL6.</p>

Alternate JournalBlood
PubMed ID17545502
PubMed Central IDPMC1976344
Grant ListR01 CA104348 / CA / NCI NIH HHS / United States